title: Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects.
abstract: A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.
authors: Department of Microbiology and Immunology, Sealy Center for Vaccine Development, Center for Biodefense and Emerging Infectious Disease, Institute for Human Infections and Immunity, Galveston, TX, USA. d.beasley@utmb.edu
authors: David W C
authors: DW
authors: Beasley